Valuation: MannKind Corporation

Market Cap 1.2B 1.06B 982M 903M 1.69B 116B 1.72B 11.74B 4.58B 56.77B 4.51B 4.41B 197B P/E 2026 *
-136x
P/E 2027 * 27.5x
Enterprise Value 1.2B 1.06B 982M 903M 1.69B 116B 1.72B 11.74B 4.58B 56.77B 4.51B 4.41B 197B EV / Sales 2026 *
2.6x
EV / Sales 2027 * 2.3x
Free-Float
98.46%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: MannKind Corporation

1 day+1.30%
1 week-3.71%
Current month-8.69%
1 month-1.02%
3 months+43.54%
6 months-28.75%
Current year-31.39%
1 week 3.71
Extreme 3.7101
4.23
1 month 3.71
Extreme 3.7101
4.55
Current year 2.23
Extreme 2.23
6.51
1 year 2.23
Extreme 2.23
6.51
3 years 2.23
Extreme 2.23
7.63
5 years 2.23
Extreme 2.23
7.63
10 years 0.67
Extreme 0.6662
7.63
Manager TitleAgeSince
Chief Executive Officer 49 24/05/2017
Director of Finance/CFO 50 21/04/2024
Chief Tech/Sci/R&D Officer - 28/09/2025
Director TitleAgeSince
Director/Board Member 82 30/09/2003
Director/Board Member 82 30/11/2003
Chairman 69 08/12/2020
Date Insider Type Main position Quantity % Market Cap.
17/07/26 Sell

General Counsel

-24,109 0.0078%
17/07/26 Sell

Director

-52,485 0.0170%
15/07/26 Fiscal year

Chief Executive Officer

1,063,720 0.3443%
Change 5-day change 1-year change 3-year change Capi.($)
+1.30%-3.71%-5.12%-12.19% 1.2B
+1.23%+0.35%+51.62%+87.98% 55.92B
+2.33%+8.51%+65.18%+70.39% 56.67B
+0.25%+0.55%-19.67%-15.22% 23.28B
+0.72%-0.05%+3.84%+409.54% 23.28B
-0.36%+5.73%+30.99%-3.58% 20.54B
-0.92%+0.99%+25.62%-29.94% 17.78B
-1.44%+5.67%+32.54%+544.11% 15.9B
-2.54%-8.73%+164.11%+289.45% 14.64B
+1.22%-0.05%+22.58%+182.63% 13.99B
Average +0.06%+0.76%+37.17%+152.32% 24.32B
Weighted average by Cap. +0.54%+3.14%+43.31%+135.33%

Financials

2026 *2027 *
Net sales 463M 407M 378M 348M 652M 44.83B 664M 4.52B 1.76B 21.87B 1.74B 1.7B 75.86B 522M 459M 426M 392M 735M 50.51B 748M 5.1B 1.99B 24.64B 1.96B 1.92B 85.47B
Net income 72K 63.32K 58.83K 54.11K 101K 6.97M 103K 703K 274K 3.4M 270K 264K 11.8M 56.82M 49.97M 46.43M 42.7M 80.07M 5.5B 81.51M 555M 217M 2.68B 213M 209M 9.31B
Net Debt - -
Logo MannKind Corporation
MannKind Corporation is a biopharmaceutical company engaged in transforming chronic disease care through patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. Its commercial assets include Afrezza, FUROSCIX and V-Go along with Tyvaso DPI. Its commercializing Afrezza (insulin human) Inhalation Powder, an ultra-rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease product, Tyvaso DPI (treprostinil) inhalation powder, is used in the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Employees
592
Date Price Change Volume
23/07/26 US$3.890 +1.30% 2,941,996
22/07/26 US$3.840 -5.19% 5,543,073
21/07/26 US$4.050 +1.76% 4,403,386
20/07/26 US$3.980 -1.24% 3,024,894
17/07/26 US$4.030 -0.25% 3,508,984
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
3.890USD
Average target price
7.594USD
Spread / Average Target
+95.21%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MNKD Stock